Metabolite Changes Following Consumption Of Different Protein Drinks In Singapore Older Adults

National University of Singapore

Status: Enrolling

Conditions: Protein Metabolism; Aging

Treatments: Dietary Supplement: Maltodextrin Drink; Dietary Supplement: Casein Protein Isolate Drink; Dietary Supplement: Soy Protein Isolate Drink; Dietary Supplement: Whey Protein Isolate Drink

Study type: Interventional

Funder types: Other

Identifiers

NCT06956131

NUS-IRB-2025-19 (Other Identifier)

S31

Details and patient eligibility

About

The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.

Full description

This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days

Enrollment: 32 estimated patients

Sex: All

Ages: 60 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• English-literate and able to give informed consent
• Adults 60 to 80 years old (inclusive)
• (If applicable) Postmenopausal
• BMI of 18·5 to 30 kg/m2 (inclusive)

Exclusion criteria

• Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention

• Weight change >3 kg in the past 3 months

• Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)

• Current smokers or have quit smoking for less than 5 years

• Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)

• If drinking ≤2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits (total 12 days)

• Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits (total 4 days)

• Taking supplements containing omega-3, magnesium, gamma-aminobutyric acid (GABA), L-theanine, melatonin and/or 5-hydroxytryptophan for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration

• Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)

  • Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: milk/dairy products (e.g., casein, whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans.

• Disease or impairment of the kidney and/or liver

• Currently diagnosed with diabetes, sleep disorders, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency

• History of diseases known to affect the central nervous system (e.g., heart disease, stroke, migraine headaches, multiple sclerosis, Parkinson's disease, mental illnesses)

• Taking antibiotics 2 weeks prior to study participation

• Taking medication known to interfere with cognitive function and mental wellbeing (e.g., benzodiazepines, antidepressants, other central nervous agents)

• Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition

• Poor peripheral venous access based on past experiences with blood drawing

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

32 participants in 4 patient groups, including a placebo group

Casein Protein Drink

Experimental group

Description:

30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water

Treatment:

Dietary Supplement: Casein Protein Isolate Drink

Whey Protein Drink

Experimental group

Description:

30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water

Treatment:

Dietary Supplement: Whey Protein Isolate Drink

Soy Protein Drink

Experimental group

Description:

30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water

Treatment:

Dietary Supplement: Soy Protein Isolate Drink

Maltodextrin Drink

Placebo Comparator group

Description:

30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water

Treatment:

Dietary Supplement: Maltodextrin Drink